Procter & Gamble Health Ltd
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]
- Market Cap ₹ 8,233 Cr.
- Current Price ₹ 4,960
- High / Low ₹ 5,500 / 3,870
- Stock P/E 35.9
- Book Value ₹ 452
- Dividend Yield 1.92 %
- ROCE 45.6 %
- ROE 33.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.9%
- Company has been maintaining a healthy dividend payout of 78.7%
Cons
- Stock is trading at 11.0 times its book value
- The company has delivered a poor sales growth of 12.0% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
687 | 798 | 867 | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | |
582 | 721 | 809 | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | |
Operating Profit | 106 | 77 | 59 | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 |
OPM % | 15% | 10% | 7% | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% |
20 | 21 | 20 | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Depreciation | 9 | 10 | 13 | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 |
Profit before tax | 117 | 88 | 67 | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 |
Tax % | 33% | 37% | 35% | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% |
78 | 56 | 43 | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | |
EPS in Rs | 47.23 | 33.66 | 26.04 | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 |
Dividend Payout % | 5% | 25% | 23% | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 12% |
3 Years: | -3% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 23% |
3 Years: | -4% |
TTM: | 19% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 14% |
3 Years: | 1% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 37% |
3 Years: | 28% |
Last Year: | 34% |
Balance Sheet
Figures in Rs. Crores
Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | |
Reserves | 467 | 506 | 538 | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | |
111 | 125 | 154 | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 274 | 338 | |
Total Liabilities | 594 | 648 | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 894 | 1,101 |
75 | 85 | 110 | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | |
CWIP | 2 | 9 | 28 | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 |
Investments | 24 | 24 | 24 | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 |
494 | 530 | 547 | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 741 | 925 | |
Total Assets | 594 | 648 | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 894 | 1,101 |
Cash Flows
Figures in Rs. Crores
Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
54 | 0 | 5 | 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | ||
-82 | 7 | 11 | -68 | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | ||
0 | -5 | -17 | -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | ||
Net Cash Flow | -28 | 3 | -1 | 4 | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 |
Ratios
Figures in Rs. Crores
Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 34 | 38 | 44 | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 |
Inventory Days | 160 | 153 | 162 | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 |
Days Payable | 48 | 37 | 40 | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 189 | 239 |
Cash Conversion Cycle | 146 | 154 | 166 | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -38 | -69 |
Working Capital Days | 77 | 70 | 74 | 69 | 52 | 94 | 42 | 22 | 23 | 9 | 18 | 16 |
ROCE % | 26% | 18% | 12% | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 46% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 22 Sep
- Communication In Respect Of Deduction Of Tax At Source (TDS) On The Amount Of Dividend Income From Procter & Gamble Health Limited ('The Company') 8 Sep
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 30 Aug
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 30 Aug
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 Aug - Find enclosed annual secretarial compliance report for the Financial Year ended June 30,2023
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Brand Portfolio
The company has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion and Livogen.[1]